Drugs / OB-002
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04791007 | Oct 2019 → Apr 2020 | — | Orion Biotechnology | Completed | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT05940844 | Jan 2024 → Apr 2025 | breast cancer, colorectal cancer, gastric cancer, malignant pancreatic neoplasm +2 | Orion Biotechnology | Withdrawn | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OB-002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05940844 ↗ |
| Known as | 5p12-rantes | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314995 ↗ |
| Known as | OB-002H | “The purpose of this study was to characterize the safety, acceptability, and pharmacokinetic profile of a gel formulation of OB-002 (OB-002H).” PMID 33749321 ↗ Apr 2021 |
| Action | Inhibit | “OB-002 is an extremely potent CCR5 antagonist” PMID 33749321 ↗ Apr 2021 |
| Target | CCR5 | “OB-002 is an extremely potent CCR5 antagonist” PMID 33749321 ↗ Apr 2021 |